On August 23, 2024, Gregory Weinhoff, the Chief Business Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), performed a significant transaction by selling 30,000 shares of the company’s stock. The sale was documented in a recent SEC filing. Following this transaction, the insider now owns 223,369 shares of Centessa Pharmaceuticals PLC.
Centessa Pharmaceuticals PLC, trading under the symbol CNTA, is a biopharmaceutical company. The company is focused on discovering, developing and delivering effective medicines to patients. Centessa Pharmaceuticals PLC aims to provide innovative treatments for various diseases with significant unmet medical needs.
Centessa Pharmaceuticals PLC shares were valued at $12.24 on the day of the insider’s most recent transaction. This price values the company at a market capitalization of around $1.456 billion.
The insider transaction history at Centessa Pharmaceuticals PLC over the past year indicates a trend where there have been more insider sales than insider purchases. Specifically, there have been six insider sales and no insider purchases. This recent sale by Gregory Weinhoff is consistent with the ongoing trend of insider behavior at the company.
For further details on Centessa Pharmaceuticals PLC’s valuation metrics such as price-to-earnings ratio, price-to-sales ratio, price-to-book ratio and price-to-free cash flow ratio, interested parties can refer to GF Value for a comprehensive analysis.
This sale by the insider may be of interest to current and potential investors as it provides insight into insider confidence and activities within the company.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
